Compare · ILMN vs LH
ILMN vs LH
Side-by-side comparison of Illumina Inc. (ILMN) and Labcorp Holdings Inc. (LH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ILMN and LH operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $24.56B, about 1.1x LH ($21.74B).
- Over the past year, ILMN is up 86.1% and LH is up 2.5% - ILMN leads by 83.6 points.
- ILMN has been more active in the news (22 items in the past 4 weeks vs 7 for LH).
- Both have 25 recent analyst ratings on file.
- Company
- Illumina Inc.
- Labcorp Holdings Inc.
- Price
- $158.13-2.55%
- $262.05-1.15%
- Market cap
- $24.56B
- $21.74B
- 1M return
- +14.02%
- +1.59%
- 1Y return
- +86.08%
- +2.47%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2000
- News (4w)
- 22
- 7
- Recent ratings
- 25
- 25
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Labcorp Holdings Inc.
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. In addition, it provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
Latest ILMN
- Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution
- SVP, Chief People Officer Leckman Patricia sold $127,068 worth of shares (784 units at $162.08), decreasing direct ownership by 3% to 22,042 units (SEC Form 4)
- Director Meister Keith A. sold $107,042,631 worth of shares (669,596 units at $159.86) (SEC Form 4)
- Chief Legal Officer Davies Scott M sold $98,400 worth of shares (615 units at $160.00), decreasing direct ownership by 3% to 21,568 units (SEC Form 4)
- VP, Chief Accounting Officer Ericksen Scott D sold $305,150 worth of shares (2,000 units at $152.57), decreasing direct ownership by 12% to 14,446 units (SEC Form 4)
- Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights
- Amendment: SEC Form 4 filed by Director Meister Keith A.
- Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
- Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research
- Illumina Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
Latest LH
- Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer
- Labcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side Effects
- Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Labcorp to Present at the Jefferies Global Healthcare Conference
- Labcorp Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form SD filed by Labcorp Holdings Inc.
- Labcorp Launches MyLabcorp™, a New AI-Powered Mobile App Designed to Help Consumers Understand Lab Results and Track Health Trends Over Time
- President & CEO Schechter Adam H sold $1,502,314 worth of shares (5,903 units at $254.50) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 107,234 units (SEC Form 4)
- Labcorp and Epic Expand Collaboration to Advance Diagnostic Integration across Hospitals and Health Systems
- SEC Form 144 filed by Labcorp Holdings Inc.